Psoriasis frequently progresses to PsA, and it has been uncertain whether drugs targeting TNF can delay or prevent it. This retrospective analysis examined progression rates in patients with severe ...

Tampa, FL - Psoriasis occurring in patients with chronic arthritic conditions treated with TNF inhibitors has been described as an adverse effect of these drugs?a paradoxical side effect, because TNF ...

Psoriasis, a chronic inflammatory skin condition characterized by dry and scaly skin lesions, affects about 7.5 million people in the United States. Psoriasis results from abnormal proliferation of ...

For patients with plaque psoriasis who initiated treatment with a first-line biologic, the average treatment cost more than doubled from 2007 to 2021 as more patients started newer IL-17 and IL-23 ...

While the link between TNF inhibitor use during pregnancy/postpartum and serious infection risk was not statistically significant, an increased risk cannot be ruled out.

Haisco Pharmaceutical Group Co. Ltd. has described compounds acting as TNF-α/tumor necrosis factor receptor superfamily member 1A (TNFR1) interaction inhibitors reported to be useful for the treatment ...

Interclass biologic switching in psoriasis improves short-term and long-term effectiveness, notably with anti–IL-23p19 agents. Infection risk increases when switching from anti–TNF-α to anti–IL-23p19, ...

Discover why psoriasis treatments may lose effectiveness and explore alternatives. Learn about the potential of biologics, systemic therapies, and more to manage symptoms.

Tumor necrosis factor (TNF) inhibitor therapy was effective in reducing the likelihood that psoriasis would progress to psoriatic arthritis (PsA), a retrospective study indicated. Among ...